TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease

Citations Over TimeTop 10% of 2018 papers

Abstract

There is considerable interest in harnessing innate immunity to treat Alzheimer's disease (AD). Here, we explore whether a decoy receptor strategy using the ectodomain of select TLRs has therapeutic potential in AD. AAV-mediated expression of human TLR5 ectodomain (sTLR5) alone or fused to human IgG4 Fc (sTLR5Fc) results in robust attenuation of amyloid β (Aβ) accumulation in a mouse model of Alzheimer-type Aβ pathology. sTLR5Fc binds to oligomeric and fibrillar Aβ with high affinity, forms complexes with Aβ, and blocks Aβ toxicity. Oligomeric and fibrillar Aβ modulates flagellin-mediated activation of human TLR5 but does not, by itself, activate TLR5 signaling. Genetic analysis shows that rare protein coding variants in human TLR5 may be associated with a reduced risk of AD. Further, transcriptome analysis shows altered TLR gene expression in human AD. Collectively, our data suggest that TLR5 decoy receptor-based biologics represent a novel and safe Aβ-selective class of biotherapy in AD.

Related Papers

• → TLR5-Derived, TIR-Interacting Decoy Peptides to Inhibit TLR Signaling(2023)6 cited
• → Fibrillar and Oligomeric β‐Amyloid as Distinct Local Biomarkers for Alzheimer's Disease(2007)22 cited
• → Pitfalls in the quantitative estimation of β-amyloid immunoreactivity in human brain tissue(1998)15 cited
• → Degradation of Serum Amyloid A in Amyloid‐Susceptible and Amyloid‐Resistant Mouse Strains(1996)9 cited
• Dicyanovinyl-substituted J147 analogue inhibits oligomerization and fibrillation of β-amyloid peptides and protects neuronal cells fromβ-amyloid-induced cytotoxicity(2015)